Pages that link to "Q44881257"
Jump to navigation
Jump to search
The following pages link to Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase (Q44881257):
Displaying 50 items.
- Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT (Q21142738) (← links)
- Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region (Q24313159) (← links)
- Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor (Q24323270) (← links)
- Cell signaling by receptor tyrosine kinases (Q24598357) (← links)
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 (Q24608143) (← links)
- Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology (Q24685914) (← links)
- Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors (Q26738567) (← links)
- Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions (Q26799387) (← links)
- Structural and functional properties of platelet-derived growth factor and stem cell factor receptors (Q26829546) (← links)
- Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location (Q26829970) (← links)
- Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms (Q26995624) (← links)
- Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? (Q27001584) (← links)
- Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia (Q27640723) (← links)
- A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases (Q27647832) (← links)
- Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation (Q27652602) (← links)
- Crystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG Conformation (Q27652985) (← links)
- A crystallographic snapshot of tyrosine trans-phosphorylation in action (Q27653072) (← links)
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients (Q27653496) (← links)
- The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2) (Q27653890) (← links)
- Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations (Q27654059) (← links)
- A G-Rich Sequence within the c-kit Oncogene Promoter Forms a Parallel G-Quadruplex Having Asymmetric G-Tetrad Dynamics (Q27657150) (← links)
- A conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulation (Q27659450) (← links)
- Structural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin Ligase (Q27665424) (← links)
- Discovery and Structure−Activity Relationship of 3-Aminopyrid-2-ones as Potent and Selective Interleukin-2 Inducible T-Cell Kinase (Itk) Inhibitors (Q27666917) (← links)
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors (Q27673353) (← links)
- Discovery of Potent and Selective Covalent Inhibitors of JNK (Q27676927) (← links)
- Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor (Q27678151) (← links)
- Sequence Determinants of a Specific Inactive Protein Kinase Conformation (Q27678722) (← links)
- Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region (Q27680371) (← links)
- Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors (Q27683558) (← links)
- Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2 (Q27683971) (← links)
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia (Q27851767) (← links)
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD (Q27852087) (← links)
- Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight (Q28293108) (← links)
- A Src-like inactive conformation in the abl tyrosine kinase domain (Q28469170) (← links)
- Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl (Q28472368) (← links)
- Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms (Q28478611) (← links)
- Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket (Q28486691) (← links)
- Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity (Q28541374) (← links)
- Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT (Q28553167) (← links)
- Computational modeling of laminin N-terminal domains using sparse distance constraints from disulfide bonds and chemical cross-linking (Q28821078) (← links)
- Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations (Q30157152) (← links)
- Feature-similarity protein classifier as a ligand engineering tool (Q30358077) (← links)
- Space-related pharma-motifs for fast search of protein binding motifs and polypharmacological targets (Q30425413) (← links)
- The energy landscape analysis of cancer mutations in protein kinases (Q31038185) (← links)
- KIT is required for hepatic function during mouse post-natal development (Q33289995) (← links)
- An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic (Q33308713) (← links)
- Sequence and structure signatures of cancer mutation hotspots in protein kinases (Q33510934) (← links)
- The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): an in silico analysis (Q33537429) (← links)
- Gastrointestinal stromal tumor and its targeted therapeutics (Q33579642) (← links)